**Table e-5**

**Tremor Patient ILS Response**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient No.** | |  | **Setting prior to ILS**\* |  | **ILS settings**\* |  | **Settings at last evaluation** |  | **DBS implant to ILS** | | |  | **Duration on ILS** |  | **FTMTRS**  **Pre/Post ILS** |  | **Response** |  | **Continue**  **ILS settings at last evaluation** |  | **Comments and reason for ILS discontinuation** | |
| **MANAGEMENT OF ADVERSE EFFECTS** | | | | | | | | | | | | | | | | | | | | | |
| ET1 |  | L: C+3-/1.5/60/130 | |  | **L: C+3-/1.3/60/125;**  **C+2-/1.3/60/125** |  | L: C+3-/1.5/60/130 |  | 3 months | | |  | 1 week |  | 30/\_\_ |  | No Benefit |  | No |  | AE: dysarthria | |
| ET4 |  | L: 2+1-/4.1/90/185 | |  | **L: C+2-/2/180/125;**  **1+2-/3/120/125** |  | **L: C+2-/2/180/125;**  **1+2-/3/120/125** |  | 91 months | | |  | 15 months |  | \_\_/\_\_ |  | Improvement |  | Yes |  | AE: dysarthria and paresthesia | |
| ET5 |  | L: C+3-/3/90/130 | |  | **L: C+3-/2.5/60/125; 2+3-/1.5/90/125** |  | **L: C+3-/2.5/60/125; 2+3-/1.5/90/125** |  | 23 months | | |  | 17 months |  | \_\_/11 |  | Improvement |  | Yes |  | AE: paresthesia | |
| **IMPROVE TREMOR** | | | | | | |  |  |
| ET2 | |  | R: C+1-/1.5/60/130  L: 2+1-/3.5/90/185 |  | R: C+1-/1.5/60/130  **L: C+0-/-/90/125;**  **C+3-/-/90/125** | | R: C+1-/1.5/60/130  L: C+1-/3.5/90/185 |  |  | 37 months | |  | Program session |  | \_\_/\_\_ |  | No Benefit |  | No |  |  | |
| ET3 | |  | L: 3+2-/4/90/185 |  | **L: 1+2-/4.5/210/125; 3+2-/5/120/125** | | L: 1+2-/4/90/185 |  |  | | 94 months |  | 1 week |  | \_\_/\_\_ |  | No Benefit |  | No |  |  | |
| MS1 | |  | L: C+3-/2.9/60/130 |  | **L: C+3-/2.9/60/125;**  **C+2-/1/60/125** | | L: C+3-/2.8/60/130 |  |  | | 4 months |  | 2 days |  | \_\_/\_\_ |  | No Benefit |  | No |  |  | |
| PD28 | |  | L: 2+1-/4/60/130 |  | **L: C+1-/2.2/60/125;**  **C+2-/2/60/125** | | 2+1-/4/60/130 |  |  | | 11 months |  | 1 week |  | \_\_/\_\_ |  | No Benefit |  | No |  |  | |

Abbreviations: \*contacts/voltage (volts) /pulse width (μs)/frequency (Hz); AE: adverse event; C: case; DBS: deep brain stimulation; ET: essential tremor; FTMTRS: Fahn Tolosa Marin Tremor Rating Scale; L: left; MS: multiple sclerosis; PD: Parkinson disease; R: right. Interleaving stimulation is in BOLD type.